Our institution participated in the BRACHY-CHOR-001 study, a phase 2 human trial in which patients with advanced chordomas received radiation in addition to a viral-based vaccine engineered to express the human brachyury tumor-associated antigen combined with human costimulatory molecules, aiming to maximize antitumor immune response [19]. This evidence concerns the gene TBX1 and chordoma.